跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 8,102 条关于
“EGFR mutations”
全部
8,102
临床试验
4,507
药物
269
机构
4
资讯
3,322
9个月前
ArriVent Initiates Pivotal Phase 3 ALPACCA Trial for Firmonertinib in EGFR PACC Mutant NSCLC
去年
Zipalertinib Shows Promise in NSCLC with EGFR Exon 20 Insertion Mutations
去年
BlossomHill Therapeutics to Present Novel OMNI-EGFR Inhibitor BH-30643 at AACR 2025 for NSCLC Treatment
去年
Dizal Submits NDA to FDA for Sunvozertinib in EGFR Exon20ins NSCLC
10个月前
ORIC Pharmaceuticals Publishes Breakthrough Research on Brain-Penetrant EGFR Inhibitor Enozertinib for Lung Cancer
去年
BlossomHill Therapeutics Advances EGFR-Mutant NSCLC Treatment with First-in-Class OMNI-EGFR Inhibitor BH-30643
去年
UCLA Researchers Receive $950,000 Grant to Launch Multi-Institutional Trial of Zipalertinib for EGFR-Mutated Cancers
去年
Lunit and AstraZeneca to Present AI Model for EGFR Mutation Prediction in NSCLC at AACR 2025
3个月前
RYBREVANT Plus LAZCLUZE Achieves Nearly 3.5-Year Median Overall Survival in Atypical EGFR-Mutated NSCLC
去年
Tagrisso Receives Positive CHMP Opinion for Advanced EGFR-Mutated NSCLC in the EU
第 1 页,共 333 页
上一页
下一页